Sinocelltech Group Ltd.

688520 · SSE

Public Market Listing

688520SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Sinocelltech Group Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
PD-1 + VEGFMultispecific antibody
Non-Small Cell Lung Cancer
Phase 3
CD38Biologic (subtype unspecified)
Multiple MyelomaSystemic Lupus ErythematosusIgA NephropathyAmyloidosis
AL Amyloidosis
Phase 2/3
PD-1 / VEGF / TGF-β receptor II (TGFβRII)Multispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (7)
April 2027 (2)
SCTC21CPhase 1/2Systemic Lupus Erythematosus (SLE)
Est. primary completion 2027-04 · NCT07538154 · CT.gov ↗
What to watch
SCTB41Phase 1/2Advanced Malignant Solid Tumours
Est. primary completion 2027-04-30 · NCT06600022 · CT.gov ↗
What to watch
July 2027 (1)
SCTB14Phase 3Non-Small Cell Lung Carcinoma (NSCLC)
Est. primary completion 2027-07 · NCT07362459 · CT.gov ↗
What to watch
September 2027 (1)
SCTC21CPhase 1/2IgA Nephropathy
Est. primary completion 2027-09 · NCT06774664 · CT.gov ↗
What to watch
December 2027 (3)
SCTC21CPhase 3Multiple Myeloma (MM)
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch
SCTC21CPhase 3Amyloidosis
Est. primary completion 2027-12 · NCT07388602 · CT.gov ↗
What to watch
SCTB14Phase 1/2Advanced Malignant Solid Tumours
Est. primary completion 2027-12-30 · NCT06304818 · CT.gov ↗
What to watch
2028 (2)
September 2028 (1)
SCTB41Phase 1/2NHL - Non-Hodgkin's Lymphoma
Est. primary completion 2028-09-30 · NCT07819188 · CT.gov ↗
What to watch
October 2028 (1)
SCTB41Phase 2NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2028-10 · NCT07609251 · CT.gov ↗
What to watch
2029 (2)
May 2029 (1)
SCTB41Phase 1/2Advanced Malignant Solid Tumor
Est. primary completion 2029-05-30 · NCT07594028 · CT.gov ↗
What to watch
June 2029 (1)
SCTB41Phase 1/2Advanced Malignant Solid Tumors
Est. primary completion 2029-06-30 · NCT07665970 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
SCTB41Phase 2/3Double Blind
Est. primary completion 2030-01-24 · NCT07662395 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$217M$118M—$786Mreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY————report ↗